Sign in →

Test Code PBORB Lyme Disease, Molecular Detection, PCR, Blood

Important Note

Now orderable in Cerner

Reporting Name

Lyme Disease PCR, B

Useful For

Supporting the diagnosis of Lyme disease in conjunction with serologic testing

 

This test should not be used to screen asymptomatic patients.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Whole Blood EDTA


Ordering Guidance


This assay does not detect Borrelia miyamotoi. If infection with this organism is suspected, order BMIPB / Borrelia miyamotoi Detection, PCR, Blood or BMIYC / Borrelia miyamotoi Detection, PCR, Spinal Fluid.



Specimen Required


Container/Tube: Lavender top (EDTA)

Specimen Volume: 1 mL

Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.


Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole Blood EDTA Refrigerated (preferred) 7 days
  Frozen  7 days

Reference Values

Negative

Reference values apply to all ages.

Day(s) Performed

June through November: Monday through Saturday

December through May: Monday through Friday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

87476

87798 x 2

87999 (if appropriate for government payers)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PBORB Lyme Disease PCR, B 90892-1

 

Result ID Test Result Name Result LOINC Value
56080 B. burgdorferi PCR, B 94247-4
38290 B. mayonii PCR, B 94248-2
38291 B. garinii/B. afzelii PCR, B 94249-0
38340 Lyme Disease PCR Comment 59464-8

Interpretation

A positive result indicates the presence of DNA from Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, or Borrelia garinii, the main agents of Lyme disease.

 

A negative result indicates the absence of detectable target DNA in the specimen. Due to the diagnostic sensitivity limitations of the polymerase chain reaction assay, a negative result does not preclude the presence of the organism or active Lyme disease.

Clinical Reference

1. Stanek G, Wormser GP, Gray J, Strle F: Lyme borreliosis. Lancet. 2012 Feb;379(9814):461-473

2. Pritt BS, Mead PS, Johnson, DK, et al: Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high levels of spirochetemia: a descriptive study. Lancet Infect Dis. 2016 May;16(5):556-564

3. Pritt BS, Respicio-Kingry LB, Sloan LM, et al: Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States. Int J Sys Evol Microbiol. 2016 Nov;66(11):4878-4880

4. Hinckley AF, Connally NP, Meek JI, et al: Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014 Sep 1;59(5):676-681

5. Lindgren E, Jaenson TGT: Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. Copenhagen, Denmark: World Health Organization; 2006

6. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995 Aug;44(31):590-591

7. Babady NE, Sloan LM, Vetter EA, et al: Percent positive rate of Lyme real-time polymerase chain reaction in blood, cerebrospinal fluid, synovial fluid, and tissue. Diagn Microbiol Infect Dis. 2008 Dec;62(4):464-466

8. Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 1995. MMWR Morb Mortal Wkly Rep. 1996 Jun;45(23):481-484

Report Available

1 to 4 days

Method Name

Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization

Testing Algorithm

For more information see Acute Tick-Borne Disease Testing Algorithm.

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.